BioNTech SE

NASDAQ:BNTX

Biotechnology

Healthcare
$83.26 -1.52%

-$1.41 today

Market cap
$20.64B
Beta
1.32
P/E (TTM)
-16.2
EPS (TTM)
-$4.93
52W Low $79.52High $124.00

Volume 1.24M

Average 1.11M

BNTX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

BioNTech SENASDAQ: BNTX

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development growth accelerates

Q2 FY2026 research & development of €551M rose 8.2% year over year, ahead of the -0.6% change in trailing-twelve-month research & development. Sequentially, it fell 2.7% from the prior quarter. Over 3 fiscal years it compounded at +9.6% a year.

Context

  • Research & development amounted to 73.3% of revenue in FY2025, down 8.6 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +8.2% holds above the trailing-twelve-month pace of -0.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
€551M-2.7% QoQ
Last fiscal yearDec 2025
€2.02B-10.3% YoY
LTMJun 2026
€2.18B-0.6% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+8.2%——
1 year-10.3%——
3-year CAGR+9.6%——
5-year CAGR——
10-year CAGR——

Research & Development history

EUR · from the income statement

Latest · FY2025
2.02B EUR
Year-over-year change
-10.3%
4-year CAGR
+20.8%

Research & Development vs competitors

How BNTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -0.6% is the 7th highest of 10, against a peer median of +11.4%.
  • Research & development amounts to 82.6% of revenue for BNTX, versus a peer median of 65.5%.
BNTX Competitors
Research & Development for BNTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€2.18B EUR-0.6%+9.6%82.6%
INCYIncyte CorporationLTM Jun 2026$2.15B USD+9.1%+8.9%37.0%
GMABGenmab A/SLTM Jun 2026$1.78B USD—-34.5%43.1%
IMCRImmunocore Holdings plcLTM Mar 2026$259.11M USD+17.2%+34.4%67.2%
XNCRXencor, Inc.LTM Jun 2026$255.77M USD+11.4%+6.3%243.6%
IBRXImmunityBio, Inc.LTM Sep 2026$252.23M USD+33.2%-5.7%138.2%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$241.88M USD-19.7%+0.6%63.8%
TGTXTG Therapeutics, Inc.LTM Sep 2026$236.22M USD+65.3%+8.5%26.3%
IMTXImmatics N.V.LTM Mar 2026€201.11M EUR+27.4%+19.9%539.2%
MGNXMacroGenics, Inc.LTM Mar 2026$135.36M USD-19.9%-12.2%86.2%
CGENCompugen Ltd.LTM Mar 2026$23.92M USD-1.0%-9.4%32.9%
Peer median (excluding BNTX) —+11.4%+3.4%65.5%

Competitors are the stored peer set for BNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.98B17.31B3.82B2.75B2.76B
Cost of Revenue2.91B3B599.8M541.3M616.47M
Gross Profit16.07B14.32B3.22B2.21B2.14B
Gross Margin84.7%82.7%84.3%80.3%77.6%
Research & Development949.2M1.54B1.78B2.25B2.02B
Selling, General & Admin327.2M541.2M557.7M599M698.2M
Operating Expenses781.4M1.67B2.53B3.52B2.76B
Depreciation & Amortization75.2M123.3M183.4M298M367.69M
EBITDA15B13.1B1.38B(367.1M)(628M)
EBITDA Margin79.1%75.7%36.1%-13.3%-22.8%
Operating Income15.28B12.64B690.4M(1.31B)(623.87M)
Operating Margin80.5%73.0%18.1%-47.8%-22.6%
Interest Income1.56M47.37M351.31M0252.24M
Interest Expense5.63M15.82M7.76M13.16M13.64M
Other Income / Expenses(237.4M)311.4M495.7M636.6M(385.46M)
Income Before Tax15.05B12.95B1.19B(677.7M)(1.01B)
Pre-Tax Margin79.3%74.8%31.1%-24.6%-36.6%
Income Tax Expense4.75B3.52B255.8M(12.4M)81.93M
Net Income10.29B9.43B930.3M(665.3M)(1.09B)
Net Margin54.2%54.5%24.4%-24.2%-39.6%
EPS (Basic)43.8738.083.87(2.77)(4.51)
EPS (Diluted)41.2137.093.83(2.77)(4.51)
Weighted Avg Shares244M243.3M240.6M240.4M241.7M
Weighted Avg Shares (Diluted)259.7M249.8M242.7M240.4M241.7M

BioNTech SE

NASDAQ:BNTX

Intrinsic Alpha fair value

Locked

Current Price

$83.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.